| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 5566 | trifluoperazine | ADCY1, ADCY3, ADCY4, ADCY6, ADCY8, ADCY9, ADRA1A, ANXA10, ANXA13, ANXA2, ANXA3, ANXA5, ANXA6, CALM1, CALY, DRD2, DRD4, DRD5, F2, FDPS, GRK7, LTB4R, MYH1, MYH2, MYH4, MYH7B, MYL1, MYL12A, MYL2, MYL7, MYL9, MYLK, MYO15A, MYO18B, MYO1C, MYO1D, MYO1E, MYO3A, MYO3B, MYO5B, MYO5C, NDUFAF3, NDUFS5, S100A4, SLC1A5, SLC5A11, SLC7A5, TNNC1, TNNI3, TNNT2 | Antipsychotic Agents, Antiemetics, Alcoholic Intoxication, Chronic, Bipolar Disorder, Catatonia, Hallucinations, Psychotic Disorders, Schizophrenia, Paranoid Schizophrenia, Brain Injuries, Mental deficiency, Alcoholism, Alcohol abuse, Bipolar disorder, Bipolar I disorder, Hallucination, Psychotic disorder, Schizophrenia, paranoid type, Brain injury |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | FGFR4 (P22455) | 0.0012 | 0 | - |
| trifluoperazine | MTOR (P42345) | 0.001 | 0 | - |
| trifluoperazine | PIK3CD (O00329) | 9e-04 | 0 | - |
| trifluoperazine | PIK3CA (P42336) | 9e-04 | 0 | - |
| trifluoperazine | VRK2 (Q86Y07) | 9e-04 | 0 | - |
| trifluoperazine | CAMK2G (Q13555) | 9e-04 | 0 | - |
| trifluoperazine | CDK19 (Q9BWU1) | 8e-04 | 0 | - |
| trifluoperazine | PRKCQ (Q04759) | 8e-04 | 0 | - |
| trifluoperazine | MAPK6 (Q16659) | 8e-04 | 0 | - |
| trifluoperazine | PAK5 (Q9P286) | 7e-04 | 0 | - |
| trifluoperazine | CDK1 (P06493) | 7e-04 | 0 | - |
| trifluoperazine | STK39 (Q9UEW8) | 6e-04 | 0 | - |
| trifluoperazine | MAPK1 (P28482) | 6e-04 | 0 | - |
| trifluoperazine | FGFR1 (P11362) | 6e-04 | 0 | - |
| trifluoperazine | CDK8 (P49336) | 5e-04 | 0 | - |
| trifluoperazine | PRKCE (Q02156) | 5e-04 | 0 | - |
| trifluoperazine | IKBKB (O14920) | 5e-04 | 0 | - |
| trifluoperazine | PKMYT1 (Q99640) | 5e-04 | 0 | - |
| trifluoperazine | MARK4 (Q96L34) | 5e-04 | 0 | - |
| trifluoperazine | CASK (O14936) | 4e-04 | 0 | - |
| trifluoperazine | EPHA7 (Q15375) | 4e-04 | 0 | - |
| trifluoperazine | SGK3 (Q96BR1) | 4e-04 | 0 | - |
| trifluoperazine | PKN2 (Q16513) | 4e-04 | 0 | - |
| trifluoperazine | GSK3B (P49841) | 3e-04 | 0 | - |
| trifluoperazine | CAMK1D (Q8IU85) | 3e-04 | 0 | - |
| trifluoperazine | BRAF (P15056) | 2e-04 | 0 | - |
| trifluoperazine | DYRK1B (Q9Y463) | 2e-04 | 0 | - |
| trifluoperazine | EPHB3 (P54753) | 2e-04 | 0 | - |
| trifluoperazine | PRKCB (P05771) | 2e-04 | 0 | - |
| trifluoperazine | PIM2 (Q9P1W9) | 1e-04 | 0 | - |
| trifluoperazine | LIMK1 (P53667) | 1e-04 | 0 | - |
| trifluoperazine | CDK4 (P11802) | 1e-04 | 0 | - |
| trifluoperazine | PKN3 (Q6P5Z2) | 1e-04 | 0 | - |
| trifluoperazine | MAPK3 (P27361) | 1e-04 | 0 | - |
| trifluoperazine | P68403 | 1e-04 | 0 | - |
| trifluoperazine | P63319 | 1e-04 | 0 | - |
| trifluoperazine | MAPK11 (Q15759) | 1e-04 | 0 | - |
| trifluoperazine | PRKCG (P05129) | 1e-04 | 0 | - |
| trifluoperazine | GSK3A (P49840) | 0 | 0 | - |
| trifluoperazine | CSNK1G1 (Q9HCP0) | 0 | 0 | - |
| trifluoperazine | P05696 | 0 | 0 | - |
| trifluoperazine | PRKCD (Q05655) | 0 | 0 | - |
| trifluoperazine | P09215 | 0 | 0 | - |
| trifluoperazine | Q64617 | 0 | 0 | - |
| trifluoperazine | RAF1 (P04049) | 0 | 0 | - |
| trifluoperazine | PRKCA (P17252) | 0 | 0 | - |
| trifluoperazine | CDK2 (P24941) | 0 | 0 | - |
| trifluoperazine | AKT3 (Q9Y243) | 0 | 0 | - |
| trifluoperazine | AKT1 (P31749) | 0 | 0 | - |
| trifluoperazine | PRKCI (P41743) | 0 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| trifluoperazine | GO:0006281 DNA repair | 1 | 1 |
| trifluoperazine | GO:0031570 DNA integrity checkpoint | 1 | 1 |
| trifluoperazine | GO:0007049 cell cycle | 0.875 | 1 |
| trifluoperazine | GO:0008283 cell population proliferation (viability) | 0.7 | 1 |
| trifluoperazine | GO:0071456 cellular response to hypoxia | 0.3333 | 0 |
| trifluoperazine | GO:0001525 angiogenesis | 0.2857 | 0 |
| trifluoperazine | GO:0008283 cell population proliferation | 0.25 | 0 |
| trifluoperazine | GO:0006954 inflammatory response | 0.2 | 0 |
| trifluoperazine | GO:0008219 cell death | 0.0625 | 0 |
| trifluoperazine | GO:0006096 glycolytic process | 0 | 0 |
| trifluoperazine | GO:0016477 cell migration | 0 | 0 |
| trifluoperazine | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| trifluoperazine | GO:0002418 immune response to tumor cell | 0 | 0 |
| trifluoperazine | GO:0010833 telomere maintenance via telomere lengthening | 0 | 0 |
| trifluoperazine | GO:0001570 vasculogenesis | 0 | 0 |
| trifluoperazine | GO:0007155 cell adhesion | 0 | 0 |
| trifluoperazine | GO:0016049 cell growth | 0 | 0 |
| trifluoperazine | GO:0006915 apoptotic process | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | Cancer(general) | 0.6236 | 0 | - |